CN Patent

CN113773262B — 哒嗪类化合物

Assigned to Jiangsu Simcere Pharmaceutical Co Ltd · Expires 2024-08-09 · 2y expired

What this patent protects

本发明提供了式(I)所示的哒嗪类化合物或其药学上可接受的盐，含有它们的药物组合物以及作为TYK2抑制剂在预防或治疗相关疾病中的用途。

USPTO Abstract

本发明提供了式(I)所示的哒嗪类化合物或其药学上可接受的盐，含有它们的药物组合物以及作为TYK2抑制剂在预防或治疗相关疾病中的用途。

Drugs covered by this patent

Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN113773262B
Jurisdiction: CN
Classification: —
Expires: 2024-08-09
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Simcere Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.